{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-034341","form_type":"8-K","ticker":"KTTA","cik":"0001841330","company_name":"Pasithea Therapeutics Corp.","filed_at":"2022-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.760051+00:00","generated_at":"2026-06-25T00:05:47.455235+00:00","sec_items":["1.01","2.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pasithea acquires Alpha-5 integrin in $3.75M stock-and-warrant deal for ALS/neurology pipeline","bullets":["Pasithea acquires all equity of Alpha-5; total consideration: 3,260,870 shares of KTTA common stock at $1.15/share (11% premium to June 21 close) plus 1M warrants at $1.88 exercise price for 5 years.","Alpha-5 holds preclinical-stage anti-alpha-5 integrin mAb targeting ALS, MS, and other neuroinflammatory disorders; IND filing expected by end of 2023.","Contingent earn-out of 2%–4% of net sales from Alpha-5's drug candidate if commercialized.","Lawrence Steinman, Pasithea's Chairman and co-founder and minority Alpha-5 owner, recused from vote; deal approved by disinterested directors.","Paul B. Manning (Alpha-5 majority owner) will own approximately 10% of Pasithea post-closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-034341","json":"https://secwatch.observer/filing/0001213900-22-034341.json","markdown":"https://secwatch.observer/filing/0001213900-22-034341.md","text":"https://secwatch.observer/filing/0001213900-22-034341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841330/000121390022034341/0001213900-22-034341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841330/000121390022034341/ea161902-8k_pasithea.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T00:05:47.455235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}